For excellence in diagnostics
– We’re bound to deliver

Medix Biochemica is a Finnish biotechnology company that develops, produces and markets monoclonal antibodies, antibody services and antigens for IVD industry as well as diagnostic rapid tests for human healthcare worldwide.

Business Activities

MedixMAB™ Antibodies & MedixAntigens

When we started the industrial-scale manufacturing of monoclonal antibodies over 30 years ago, we created a new paradigm for the antibody industry. Now our product range covers monoclonal antibodies and antigens for a variety of markers.

Learn more

MedixMAB™ Contract Manufacturing

We offer a highly cost-effective service for in vitro monoclonal antibody and recombinant antigen production. Our customised turnkey contract manufacturing service makes antibody and antigen production both effortless and worry-free, with our fully certified quality control system.

Learn more

Actim® Rapid Tests

Actim® Rapid Tests give results within minutes. They are specifically developed for use at point-of-care and in medical emergencies when quick and accurate diagnosis can make all the difference.

Learn more

Our core competencies are
at the heart of everything we do

  • Flexible production – from milligrams to hundreds of grams
  • Constant quality – from batch to batch
  • Quick and accurate deliveries globally
  • Competitive pricing

Standing behind the quality

    Our products and operations meet the needs and expectations of our customers.
    We are committed to high quality and pro activity in activities at all levels, we continuously improve of our operations and skills.
    We develop products to the diagnostic field, which are reliable, suitable for the intended use, safe and effective and their performance is scientifically justified.
    We comply with the regulatory requirements and standards relevant to our field of business.

Company Milestones

Medix Biochemica is proud to say that we are one of the first companies in the world to produce monoclonal antibodies, starting only three years after Köhler and Milstein published their Nobel Prize winning work on the subject. Medix Biochemica was established in 1985 to meet the growing demand for developing and producing monoclonal antibodies.

1959     Minerva Foundation founded
1964     Medix Ltd. founded
1970     Reagent manufacturing established
1979     Manufacturing of monoclonal antibodies established
1985     Medix Biochemica founded
1990     Rapid test manufacturing established in Joensuu factory
1994     First Actim tests released
2003     ISO 13485 compliance
2006     FDA QSR compliance
2015     New facilities in Espoo
2016     Medix Biochemica China established
2018     Medix Biochemica USA established
2019     Lee Biosolutions acquired
2020     Biostride Inc. acquired
2020     EastCoast Bio acquired

Career with us!

Medix Biochemica employs over 180 highly trained professionals. Review the open positions and apply online.

If you are interested in becoming one of us, please click the following link to see our open vacancies: Open positions and applications and apply for positions online. If there are not any vacancies that suit your interest, you can send us an open application.

Contact Information

Contact Us

Please don’t hesitate to contact us – we look forward to hearing from you!

Get in contact